# EDGAR Filing Document

**Accession Number:** 0000921114
**File Stem:** 0001104659-25-110351
**Filing Date:** 2025-11
**Character Count:** 20632
**Document Hash:** 64e03ece437fbce35a9698fe74485493
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001104659-25-110351.hdr.sgml**: 20251112

**ACCESSION NUMBER**: 0001104659-25-110351

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 15

**CONFORMED PERIOD OF REPORT**: 20251112

**ITEM INFORMATION**: Results of Operations and Financial Condition

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20251112

**DATE AS OF CHANGE**: 20251112

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Armata Pharmaceuticals, Inc.
- **CENTRAL INDEX KEY:** 0000921114
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 911549568
- **STATE OF INCORPORATION:** WA
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-37544
- **FILM NUMBER:** 251472784

**BUSINESS ADDRESS:**
- **STREET 1:** 5005 MCCONNELL AVE
- **CITY:** LOS ANGELES
- **STATE:** CA
- **ZIP:** 90066
- **BUSINESS PHONE:** 310-665-2928

**MAIL ADDRESS:**
- **STREET 1:** 5005 MCCONNELL AVE
- **CITY:** LOS ANGELES
- **STATE:** CA
- **ZIP:** 90066

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** AmpliPhi Biosciences Corp
- **DATE OF NAME CHANGE:** 20130222

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** TARGETED GENETICS CORP /WA/
- **DATE OF NAME CHANGE:** 19940331

?xml version='1.0' encoding='ASCII'? ARMATA PHARMACEUTICALS, INC._November 12, 2025

------

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, DC 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the**

**Securities Exchange Act of 1934**

Date of report (Date of earliest event reported)**: November 12, 2025**

**ARMATA PHARMACEUTICALS, INC.**

(Exact name of Registrant as specified in its charter)

---

| | | |
|:---|:---|:---|
| **Washington** | **001-37544** | **91-1549568** |
| (State or other jurisdiction of<br>incorporation or organization) | (Commission File Number) | (IRS Employer Identification No.) |

---

---

| | |
|:---|:---|
| **5005 McConnell Avenue**<br>**Los Angeles, California** | <br>**90066** |
| (Address of principal executive offices) | (Zip Code) |

---

**(310) 655-2928**

(Registrant's Telephone number)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Registrant under any of the following provisions (see General Instruction A.2. below):

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| Title of Each Class | Trading Symbol(s) | Name of Each Exchange on Which Registered |
| **Common Stock** | **ARMP** | **NYSE American** |

---

------

**Item 2.02** **Results of Operations and Financial Condition.**

On November 12, 2025, the Company announced its financial results for the three and nine months ended September 30, 2025, in the press release furnished hereto as Exhibit 99.1.

The information in this Item 2.02 and the attached Exhibit 99.1 is being furnished and shall not be deemed "filed" for the purposes of Section 18 of the Securities and Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section. The information in this Item 2.02 and the attached Exhibit 99.1 shall not be incorporated by reference into any registration statement or other document pursuant to the Securities Act of 1933, as amended.

**Item 9.01** **Financial Statements and Exhibits.**

**(d)** **Exhibits.**

---

| | | |
|:---|:---|:---|
| **ExhibitNo.** |  | **Description** |
| 99.1 |  | [Press Release, dated November 12, 2025.](armp-20251112xex99d1.htm) |
| 104 |  | Cover Page Interactive Data File (embedded within Inline XBRL document). |

---

#### SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
| Date: November 12, 2025 | **Armata Pharmaceuticals, Inc.** | **Armata Pharmaceuticals, Inc.** |
|  | By: | /s/ David House |
|  | Name: | David House |
|  | Title: | Senior Vice President, Finance and<br>Principal Financial Officer |

---

## Exhibit 99.1

![Graphic](armp-20251112xex99d1001.jpg)

**Exhibit 99.1**

**Armata Pharmaceuticals Announces Third Quarter 2025 Results and Provides Corporate Update**

LOS ANGELES, California, November 12, 2025 - Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a clinical-stage biotechnology company focused on the development of high-purity, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections, today announced financial results for its third quarter ended September 30, 2025, and provided a corporate update.

**Third Quarter 2025 and Recent Developments:** 

● Highlighted positive results from Phase 2a "diSArm" study of Armata's lead therapeutic phage candidate, AP-SA02, as a potential treatment for complicated *Staphylococcus aureus* ()"*S. aureus*") bacteremia ("SAB") at IDWeek 2025 <sup>TM</sup> , on October 22 in Atlanta, Georgia. The abstract was accepted as a late-breaking abstract for oral presentation and was presented by Dr. Loren G. Miller, M.D., M.P.H., Professor of Medicine, David Geffen School of Medicine at UCLA, Chief, Division of Infectious Diseases at Harbor-UCLA Medical Center and the Lundquist Institute.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;o AP-SA02 combined with Best Available Antibiotic Therapy ("BAT") had a higher and earlier cure rate compared to placebo (BAT alone) in patients with complicated SAB at day 12 as assessed by both blinded site investigators and independent adjudicators. Additionally, patients who received AP-SA02 demonstrated 100% response rate without relapse one week post-BAT and 28 days later at End of Study when compared to the placebo (BAT alone) group which showed approximately 25% lack of response or relapse at both timepoints.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;o AP-SA02 was well-tolerated with clinical efficacy against both methicillin-resistant *S. aureus* and methicillin-sensitive *S. aureus*, and patients treated with AP-SA02 showed trends toward rapid normalization of key predictors of mortality and complications in SAB including C-reactive protein and interleukin-10, shorter time to negative blood culture, quicker time to resolution of signs and symptoms at the infection site, and shorter intensive care unit and hospital utilization.

● Announced that its state-of-the-art current Good Manufacturing Practice ("cGMP") manufacturing facility in Los Angeles, California, has been formally commissioned. Full production runs have been completed with no issues or concerns.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;o Armata's 56,000 square foot facility includes 10,000 square feet of cGMP clean rooms, an automated fill and finish suite, and quality control laboratories, to support future clinical trials and full commercialization as well as potential partnering and contract manufacturing opportunities.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;o Aligns with the federal government's focus on onshoring manufacturing to secure the supply chain of essential medicines for the health and safety of the American people.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;o Aligns with the need to confront the growing antimicrobial resistance crisis and the risk of bacterial escape from current antibiotics.

● Entered into a secured credit agreement with Innoviva Strategic Opportunities LLC, a wholly owned subsidiary of Innoviva, Inc., Armata's largest shareholder, for a loan of $15.0 million that will mature on January 11, 2029, the proceeds of which are being used to continue to advance development of AP-SA02.

● Further advanced bacteriophage science through a structural biology publication in the *Journal of Molecular Biology*.

● Participated in the H.C. Wainwright 27 <sup>th</sup> Annual Global Investment Conference.

"Compelling efficacy data from the Phase 1b/2a randomized controlled study of intravenously administered AP-SA02, including the favorable safety and tolerability profile, underscore the precision infection control enabled by Armata's well-characterized, high-purity phage cocktails, and provide strong rationale for advancement of AP-SA02 into late-stage clinical development," stated Dr. Deborah Birx, Chief Executive Officer of Armata. "Subject to review and feedback from the U.S. Food and Drug Administration, we are committed to developing a superiority pivotal trial with the goal of introducing AP-SA02 as a new standard of care for complicated *Staphylococcus aureus* bacteremia, a common, extremely severe, and often deadly infection."

"With the full commissioning of our state-of-the-art cGMP manufacturing facility in Los Angeles, California, we are now operationally ready to scale production for late-stage clinical development. We reiterate our commitment to U.S.-based manufacturing in support of the federal government's efforts to secure the pharmaceutical supply chain through onshore manufacturing of essential medicines. We have made tremendous progress this year advancing phage-based therapeutics as potential treatments for both acute and chronic bacterial infections, and with line-of-site to the potential initiation of a Phase 3 study in 2026, we believe we are well positioned to bring new hope to patients with significant unmet medical need, while creating long-term value for our shareholders," Dr. Birx concluded.

**Third Quarter 2025 Financial Results**

**Grant and Award Revenue.** The Company recognized grant and award revenue of $1.2 million for the three months ended September 30, 2025, as compared to $3.0 million in the comparable period in 2024. This represents the Medical Technology Enterprise Consortium's share of the costs incurred for the Company's AP-SA02 program for the treatment of SAB.

------

![Graphic](armp-20251112xex99d1001.jpg)

**Research and Development.** Research and development expenses for the three months ended September 30, 2025 were approximately $5.8 million, compared to approximately $9.5 million for the comparable period in 2024 reflecting completion of two Phase 2 clincial trials and enhanced operational efficiency. The Company continues to invest in clinical-related expenses associated with its primary development programs.

**General and Administrative.** General and administrative expenses for the three months ended September 30, 2025 were approximately $3.1 million, compared to approximately $3.2 million for the comparable period in 2024.

**Loss from Operations.** Loss from operations for the three months ended September 30, 2025 was approximately $7.8 million, compared to a loss from operations of approximately $9.8 million for the comparable period in 2024.

**Cash and Cash Equivalents.** As of September 30, 2025, Armata held approximately $14.8 million of unrestricted cash and cash equivalents, compared to $9.3 million as of December 31, 2024.

As of November 4, 2025, approximately 36.3 million common shares were outstanding.

**About Armata Pharmaceuticals, Inc.**

Armata is a clinical-stage biotechnology company focused on the development of high-purity pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its proprietary bacteriophage-based technology. Armata is developing and advancing a broad pipeline of natural and synthetic phage candidates, including clinical candidates for *Pseudomonas aeruginosa, Staphylococcus aureus*, and other pathogens. Armata is committed to advancing phage therapy with drug development expertise that spans bench to clinic including in-house phage-specific current Good Manufacturing Practices ("cGMP") manufacturing to support full commercialization.

**Forward Looking Statements**

This communication contains "forward-looking" statements as defined by the Private Securities Litigation Reform Act of 1995. These statements relate to future events, results or to Armata's future financial performance and involve known and unknown risks, uncertainties and other factors which may cause Armata's actual results, performance or events to be materially different from any future results, performance or events expressed or implied by the forward-looking statements. In some cases, you can identify these statements by terms such as "anticipate," "believe," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "should," "will," "would" or the negative of those terms, and similar expressions. These forward-looking statements reflect management's beliefs and views with respect to future events and are based on estimates and assumptions as of the date of this communication and are subject to risks and uncertainties including risks related to Armata's development of bacteriophage-based therapies; ability to staff and maintain its production facilities under fully compliant cGMP; ability to meet anticipated milestones in the development and testing of the relevant product; ability to be a leader in the development of phage-based therapeutics; ability to achieve its vision, including improvements through engineering and success of clinical trials; ability to successfully complete preclinical and clinical development of, and obtain regulatory approval of its product candidates and commercialize any approved products on its expected timeframes or at all; and Armata's estimates regarding anticipated operating losses, capital requirements and needs for additional funds. Additional risks and uncertainties relating to Armata and its business can be found under the caption "Risk Factors" and elsewhere in Armata's filings and reports with the U.S. Securities and Exchange Commission (the "SEC"), including in Armata's Annual Report on Form 10-K, filed with the SEC on March 21, 2025, and in its subsequent filings with the SEC.

Armata expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Armata's expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based.

**Media Contacts:**

**At Armata:**

Pierre Kyme

ir@armatapharma.com

310-665-2928

**Investor Relations:**

Joyce Allaire

LifeSci Advisors, LLC

jallaire@lifesciadvisors.com

212-915-2569

------

![Graphic](armp-20251112xex99d1001.jpg)

**Armata Pharmaceuticals, Inc.**

**Condensed Consolidated Balance Sheets**

**(in thousands)**

**(unaudited)**

---

| | | |
|:---|:---|:---|
|  | **September 30, 2025** | **December 31, 2024** |
| **Assets** |  |  |
| **Current assets** |  |  |
| &nbsp;&nbsp;Cash and cash equivalents | $14756 | $9291 |
| &nbsp;&nbsp;Prepaid expenses and other current assets | 1415 | 1273 |
| &nbsp;&nbsp;Other receivables | 759 | 744 |
| **Total current assets** | 16930 | 11308 |
| Property and equipment, net | 12560 | 13241 |
| Operating lease right-of-use asset | 39917 | 41687 |
| Intangible assets, net | 13746 | 13746 |
| Other long term assets | 6363 | 6455 |
| **Total assets** | $89516 | $86437 |
| **Liabilities and stockholders' deficit** |  |  |
| Accounts payable, accrued and other current liabilities | 8870 | 9295 |
| Convertible Loan, current | 48088 |  |
| Term debt, current | 82992 | 38954 |
| **Total current liabilities** | $139950 | $48249 |
| Convertible Loan, non-current |  | 32897 |
| Term debt, non-current | 15240 | 22539 |
| Operating lease liabilities, net of current portion | 26837 | 27694 |
| Deferred tax liability | 3077 | 3077 |
| **Total liabilities** | 185104 | 134456 |
| **Stockholders' deficit** | (95588) | (48019) |
| **Total liabilities and stockholders' deficit** | $89516 | $86437 |

---

------

![Graphic](armp-20251112xex99d1001.jpg)

**Armata Pharmaceuticals, Inc.**

**Condensed Consolidated Statements of Operations**

**(in thousands, except share and per share data)**

**(unaudited)**

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **Three Months Ended**  | **Three Months Ended**  | **Nine Months Ended**  | **Nine Months Ended**  |
|  | **September 30,**  | **September 30,**  | **September 30,**  | **September 30,**  |
|  | **2025** | **2024** | **2025** | **2024** |
| **Grant and award revenue** | $1159 | $2973 | $3819 | $3939 |
| **Operating expenses** |  |  |  |  |
| &nbsp;&nbsp;Research and development | 5824 | 9485 | 17647 | 25975 |
| &nbsp;&nbsp;General and administrative | 3111 | 3244 | 8983 | 9861 |
| &nbsp;&nbsp;Total operating expenses  | 8935 | 12729 | 26630 | 35836 |
| **Operating loss** | (7776) | (9756) | (22811) | (31897) |
| **Other income (expense)** |  |  |  |  |
| &nbsp;&nbsp;Interest income | 90 | 294 | 257 | 567 |
| &nbsp;&nbsp;Interest expense | (4346) | (2923) | (11756) | (7462) |
| &nbsp;&nbsp;Change in fair value of the Convertible Loan  | (14643) | 6904 | (15191) | 17276 |
| **Total other income (expense), net** | (18899) | 4275 | (26690) | 10381 |
| **Net loss** | $(26675) | $(5481) | $(49501) | $(21516) |
| Per share information: |  |  |  |  |
| Net loss per share, basic and diluted | $(0.74) | $(0.15) | $(1.37) | $(0.60) |
| Weighted average shares outstanding, basic and diluted | 36226285 | 36180124 | 36201674 | 36153388 |

---

------

![Graphic](armp-20251112xex99d1001.jpg)

**Armata Pharmaceuticals, Inc.**

**Condensed Consolidated Statements of Cash Flows**

**(in thousands)**

**(unaudited)**

---

| | | |
|:---|:---|:---|
|  | **Nine Months Ended September 30,**  | **Nine Months Ended September 30,**  |
|  | **2025** | **2024** |
| **Operating activities:** |  |  |
| Net loss | $(49501) | $(21516) |
| Adjustments required to reconcile net loss to net cash used in operating activities: |  |  |
| &nbsp;&nbsp;Depreciation expense | 1113 | 945 |
| &nbsp;&nbsp;Stock-based compensation expense | 1978 | 2539 |
| &nbsp;&nbsp;Change in fair value of the Convertible Loan | 15191 | (17276) |
| &nbsp;&nbsp;Non-cash interest expense | 11739 | 7483 |
| &nbsp;&nbsp;Change in right-of-use asset | 1770 | 1489 |
| &nbsp;&nbsp;Changes in operating assets and liabilities | (1379) | (3288) |
| **Net cash used in operating activities** | (19089) | (29624) |
| **Investing activities:** |  |  |
| Purchases of property and equipment | (490) | (1956) |
| **Net cash used in investing activities** | (490) | (1956) |
| **Financing activities:** |  |  |
| Proceeds from issuance of term debt, net of issuance costs  | 25000 | 34889 |
| Payments for taxes related to net share settlement of equity awards | (46) | (61) |
| Proceeds from exercise of stock options  |  | 130 |
| **Net cash provided by financing activities** | 24954 | 34958 |
| Net increase in cash, cash equivalents and restricted cash | 5375 | 3378 |
| Cash, cash equivalents and restricted cash, beginning of period | 14771 | 19243 |
| Cash, cash equivalents and restricted cash, end of period | $20146 | $22621 |

---

---

| | | |
|:---|:---|:---|
|  | **Nine Months Ended September 30,**  | **Nine Months Ended September 30,**  |
|  | **2025** | **2024** |
| Cash and cash equivalents | $14756 | $17141 |
| Restricted cash | 5390 | 5480 |
| Cash, cash equivalents and restricted cash | $20146 | $22621 |

---

------